StockNews.com Initiates Coverage on Bio-Path with 'Sell' Rating StockNews.com began coverage of Bio-Path Holdings, assigning a "sell" rating to the struggling biotech firm. The stock, currently trading at $0.18, has significantly declined from its one-year high of $7.67, reflecting ongoing investor concerns about the company's financial health and clinical progress.3